Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2015-10-28
|
ASP2215 - gilteritinib |
acute myeloid leukemia |
3 |
Astellas Pharma (Japan) |
Cancer - Oncology |
2015-10-28
|
obeticholic acid (OCA) |
NASH (non-alcoholic steatohepatitis) |
2 |
Intercept Pharmaceuticals (USA - NY) Sumitomo Dainippon Pharma (Japan) |
Liver diseases - Hepatic diseases |
2015-10-27
|
lifitegrast |
dry eye disease |
3 |
Shire (UK - USA) |
Ophtalmological diseases |
2015-10-27
|
Onivyde™ (MM-398 - nanoliposomal irinotecan injection) |
previously untreated, metastatic pancreatic adenocarcinoma |
2 |
Baxalta (USA - IL) Merrimack Pharmaceuticals (USA - MA) |
Cancer - Oncology |
2015-10-27
|
CureXcell® |
diabetic foot ulcers |
3 |
Macrocure (Israel) |
Metabolic diseases - Cardiovascular diseases - Regenerative Medicine |
2015-10-26
|
ABP-700 |
general anesthesia, procedural sedation |
1 |
The Medicines Company (USA - NJ) |
CNS diseases |
2015-10-26
|
ASP8273 - naquotinib mesylate |
non-small cell lung cancer (NSCLC) |
3 |
Astellas Pharma (Japan) |
Cancer - Oncology |
2015-10-25
|
azacitidine |
nasopharyngeal neoplasms |
2 |
Celgene (USA - NJ) |
Cancer - Oncology - Rare diseases |
2015-10-25
|
Sativex® (Delta-9-Tetrahydro-cannabinol (THC) and Cannabidiol (CBD) |
pain in patients with advanced cancer |
3 |
GW Pharmaceuticals (UK) Otsuka Pharmaceuticals (Japan) |
Cancer - Oncology - CNS diseases |
2015-10-23
|
APR-246 in combination with carboplatin and pegylated doxorubicin |
ovarian cancer |
1-2 |
Aprea (Sweden) |
Cancer - Oncology - Rare diseases |
2015-10-23
|
house dust mite sublingual immunotherapy tablet (STG320) |
allergic asthma |
2 |
Ares Allergy (UK) |
Allergic diseases - Inflammatory diseases - Respiratory diseases |
2015-10-22
|
roxadustat |
anemia associated with chronic kidney disease (CKD) |
2 |
FibroGen (USA - CA) |
Kidney diseases - Renal diseases |
2015-10-22
|
margetuximab and pembrolizumab |
advanced HER2-positive gastric cancer |
1b-2 |
Macrogenics (USA - MD) Merck&Co (USA - NJ) |
Cancer - Oncology |
2015-10-21
|
avelumab in combination with crizotinib or lorlatinib (PF-06463922) |
non-small cell lung cancer (NSCLC) |
2 |
Pfizer (USA - NY) |
Cancer - Oncology |
2015-10-20
|
SENS-200 |
hearing loss resulting from acoustic trauma |
preclinical |
Sensorion (France) |
Otorhinolaryngology |
2015-10-20
|
RXI-109 |
hypertrophic scar |
2 |
RXi Pharmaceuticals (USA - MA) |
Dermatological diseases |
2015-10-19
|
selinexor (KPT-330 - (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide) |
multiple myeloma |
1-2 |
Karyopharm Therapeutics (USA - MA) |
Cancer - Oncology |
2015-10-16
|
AG-221 (enasidenib) |
acute myeloid leukemia (AML) |
3 |
Celgene (USA - NJ) Agios Pharmaceuticals (USA -MA) |
Cancer - Oncology |
2015-10-16
|
lenvatinib in combination with everolimus |
metastatic renal cell carcinoma (mRCC) following prior VEGF-targeted therapy |
2 |
Eisai (Japan) |
Cancer - Oncology |
2015-10-16
|
|
|
|
|
|